Our CW Innovation programme, run in partnership with Chelsea and Westminster Hospital NHS Foundation Trust, has partnered with Novartis Pharmaceuticals UK, Medtronic ltd and RYSE Asset Management to launch the Novartis Biome UK Heart Health Catalyst 2022.

The ambitious initiative has a bold aim – to identify and implement solutions that empower patients to improve their heart health, and to help prevent future heart attacks or strokes through home-based digital solutions. The focus is on the major risk factors, non-invasive ways of lipid testing and blood pressure management using software as a medical device (SaMD).

Applications are open to health-tech start-up founders, researchers, and technologists working on innovative solutions to enable system-wide change in cardiovascular disease (CVD) patient care pathways.

The Novartis Biome UK is leading this first of its kind investor partnership, combining its patient pathway knowledge with Medtronic’s experience as the global leader in healthcare technology. RYSE Asset Management, the specialist healthcare investor, will provide up to £3 million in investment and our CW Innovation programme will work to establish a real-world clinical evaluation for selected solutions.

The Novartis Biome Heart Health Catalyst 2022 aims to spark a revolution in CVD care and successful applicants will receive:

• Unrivalled support and knowledge from industry-leading and investor partners
• Investment of up to £3 million and access to a global network of established distribution partners from RYSE Asset Management
• Access to the Novartis Biome UK system
• Immediate NHS pilot and validation opportunities.

Chris Chaney, Chief Executive Officer at CW+ and co-lead of CW Innovation, said: “The COVID-19 pandemic has demanded the radical acceleration of our digital health programmes and this, coupled with a surge in new thinking and innovation across our organisation, makes the launch of the Novartis Biome UK Heart Health Catalyst 2022 both timely and relevant.

“We are therefore delighted to collaborate on this new initiative, working with partners, and providing the winner with the opportunity to test and scale their innovation at Chelsea and Westminster Hospital NHS Foundation Trust as part of our flagship CW Innovation programme.

“In this period of significant change and challenge, our absolute focus is on providing the best possible care for our patients, and we look forward to working with the winners of the Catalyst to help improve and enhance the care and experience of CVD patients.”

Applications for the Novartis Biome UK Heart Health Catalyst 2022 open today and close on 31 August 2022. Shortlisted organisations and individuals will be invited to a Pitchfest in front of an expert audience from across the healthcare system at the Healthcare Excellence Through Technology (HETT) conference on 27/28 September 2022, where the winners will subsequently be announced.

Find out more about the Novartis Biome UK Heart Health Catalyst 2022 and apply here:

https://biome.novartis.com/innovation–hubs/novartis–biome–uk/uk–health–catalyst–2022https://biome.novartis.com/innovation-hubs/novartis-biome-uk/uk-health-catalyst-2022-application-form.